MANUFACTURING ARTICLES
-
Comparing Advanced Modality Needs, Part 2: Regulatory And Market Access
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics differ considerably in regulatory requirements, commercial viability, and implications for delivery.
-
Scaling Personalization: Inside The Manufacturing & Analytical Hurdles Of mRNA Cancer Immunotherapies
As we know from the autologous cell therapies that have come before us, manufacturing and scaling personalized products is no mean feat, and there are a handful of efforts we need to be tackling today to realize a more efficient and (ideally) decentralized manufacturing process. Fortunately for us, the panel had a few ideas on what it will take to make our analytical development and manufacturing more efficient processes.
-
The Hidden Biology Of RNA Impurities: When Manufacturing Changes Therapeutic Behavior
Two mRNA batches may contain the same intended therapeutic sequence yet produce different biological responses. One explanation lies in the unintended RNA species generated during manufacturing.
-
Comparing Advanced Modality Needs, Part 1: Manufacturing
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
-
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions
This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing
Let's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Learn how precise sizing methods reveal nucleosome patterns in cfDNA and help distinguish true signal from extraction‑related artifacts for more reliable genomic analysis.
-
The biopharmaceutical industry is in the midst of a period of rapid growth. It is also experiencing increasing uncertainty, diversification of modalities, and cost pressure. To address these challenges, the industry will need to embrace the facility of the future – a new biomanufacturing paradigm. This infographic identifies market trends challenging biopharmaceutical companies, business drivers to meet market needs, as well as requirements and aspirations for the factory of the future.
-
Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.
-
Learn about key regulatory concepts and ways to accelerate and reduce risk throughout the drug development journey.
-
Discover how osmolality can be applied throughout the bioprocessing workflow for RNA, and recognize the importance of this sensitive measurement, from formulation optimization to cryopreservation techniques.
-
Here we describe screening of detergents for release of adenovirus from HEK293 host cells to replace the traditionally used detergent Triton™.
-
Explore the advantages of paperless manufacturing, the importance of incorporating a digital strategy early in the process, and how digital solutions for mRNA manufacturing can help enhance production.